IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Company signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CAESAREA, Israel, July 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM)...